公开(公告)号：US20230330274A1

公开(公告)日：2023-10-19

申请号：US18320890

申请日：2023-05-19

申请人： Lantheus Medical Imaging, Inc.

发明人： Simon P. Robinson ,  Robert W. Siegler ,  Nhung Tuyet Nguyen ,  David C. Onthank ,  Tarakeshwar Vishwanath Anklekar ,  Charles Chester Van Kirk

IPC分类号： A61K49/22 ,  C07F9/09 ,  A61B8/08 ,  C07F9/10

CPC分类号： A61K49/223 ,  C07F9/09 ,  A61K49/227 ,  A61B8/481 ,  A61K49/226 ,  C07F9/106

摘要： Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

公开(公告)号：US20180325924A1

公开(公告)日：2018-11-15

申请号：US15976481

申请日：2018-05-10

申请人： The Board of Trustees of the University of Illinois, a body corporate and politic of the stat

发明人： PAPASANI V. SUBBAIAH ,  Poorna Yalagala ,  Sugasini Dhavamani

IPC分类号： A61K31/661 ,  C07F9/10 ,  A61K9/107 ,  A61P25/28

CPC分类号： A61K31/661 ,  A61K9/1075 ,  A61P25/28 ,  C07F9/10 ,  C07F9/106

摘要： Described herein are at least compounds and formulations that can be or contain a docosahexaenoic acid-lysophosphatidylcholine (DHA-LPC) and/or eicosapenteanoic acid-lysophosphatidylcholine (EPA-LPC). Also described herein are at least methods of making and using the compositions and formulations DHA-LPC and/or EPA-LPC.

公开(公告)号：US20170246197A1

公开(公告)日：2017-08-31

申请号：US15430715

申请日：2017-02-13

申请人： Vascular Biogenics Ltd.

发明人： Gideon HALPERIN ,  Eti KOVALEVSKI-ISHAI

IPC分类号： A61K31/685 ,  A61K9/48 ,  A61K9/00

CPC分类号： A61K31/685 ,  A61K9/0053 ,  A61K9/48 ,  A61K31/661 ,  C07F9/106 ,  C07F9/1411

摘要： Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4′-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).

公开(公告)号：US20170218027A1

公开(公告)日：2017-08-03

申请号：US15350792

申请日：2016-11-14

申请人： KODE BIOTECH LIMITED

发明人： Nicolai Vladimirovich Bovin ,  Stephen Micheal Henry ,  Igor Leonidovich Rodionov ,  Critsina-Simona Weinberg ,  Alexander Borisovich Tuzikov

IPC分类号： C07K9/00

CPC分类号： C07K9/001 ,  A61K47/544 ,  A61K47/65 ,  C07F9/106 ,  C07F9/572 ,  C07F9/6561 ,  C07K7/06 ,  C07K7/08 ,  G01N33/80

摘要： The invention relates to functional lipid constructs and their use in diagnostic and therapeutic applications, including serodiagnosis, where the functional moiety is carbohydrate, peptide, chemically reactive group, conjugator or fluorophore.

公开(公告)号：US20170101425A1

公开(公告)日：2017-04-13

申请号：US15317441

申请日：2015-06-09

申请人： Chemi S.P.A.

发明人： Lorenzo De Ferra ,  Mauro Anibaldi ,  Maurizio Zenoni ,  Fabrizio Cocchi

IPC分类号： C07F9/10 ,  G01N21/49 ,  G01N30/02 ,  B01D15/08

CPC分类号： C07F9/103 ,  B01D15/08 ,  C07F9/091 ,  C07F9/106 ,  C07F9/65742 ,  G01N21/49 ,  G01N30/02 ,  G01N2030/027

摘要： A process for the purification of L-α-glycerophosphorylcholine is described, wherein L-α-glycerophosphorylcholine is crystallized from DMSO or from a mixture of DMSO with at least another solvent, preferably selected from water, alcohol, halogenated solvents, ethers, esters and/or amides. Such a process allows to obtain L-α-glycerophosphorylcholine having a purity greater than 99.5%, preferably greater than 99.7%, even more preferably greater than or equal to 99.9%. A method for determining the purity of L-α-glycerophosphorylcholine is also described, comprising the elution of L-α-glycerophosphorylcholine through an HPLC column having an amino stationary phase, and subsequent detection of L-α-glycerophosphorylcholine itself, and any impurity thereof, by means of an Evaporative Light Scattering Detector type.

公开(公告)号：US09539273B2

公开(公告)日：2017-01-10

申请号：US14793371

申请日：2015-07-07

申请人： Thomas Meehan ,  Quyen Ong

发明人： Thomas Meehan ,  Quyen Ong

IPC分类号： A61K47/24 ,  C07F9/6521 ,  A61K31/7048 ,  C07F9/6558 ,  C07F9/10 ,  A61K47/48

CPC分类号： A61K31/7048 ,  A61K45/06 ,  A61K47/48061 ,  A61K47/545 ,  C07F9/106 ,  C07F9/65583

摘要： The present application discloses a targeting composition that actively targets chitin-like substances, such as those found in fungi, protists, arthropods, Alzheimer's plaques, etc. Methods are disclosed for preparation of chitin-targeted drug delivery vehicles composed of the targeting composition and one or more bioactive compounds.

摘要翻译： 本申请公开了一种靶向组合物，其主动靶向几丁质样物质，例如在真菌，原生生物，节肢动物，阿尔茨海默病斑块等中发现的物质。方法公开用于制备由靶向组合物和一种靶向组合物组成的甲壳素靶向药物递送载体 或更多的生物活性化合物。

公开(公告)号：US09499572B2

公开(公告)日：2016-11-22

申请号：US14888802

申请日：2014-04-30

申请人： Pethmark AB

发明人： David Wensbo Posaric ,  Karl-Erik Berquist

IPC分类号： C07F9/11 ,  C07F9/10 ,  G01N24/08

CPC分类号： C07F9/106 ,  C07F9/11 ,  G01N24/08

摘要： The present invention discloses a composition comprising a compound of formula I and a deuterated solvent. The deuterated solvent is miscible with water in any proportion at a temperature of 20 to 25° C. and comprises less than 5% residual 1H-isotopes. The concentration of the compound of formula I may advantageously be determined by 1H-QNMR. Methods of production of the composition and salts of compounds of formula I, as well as related analogs and novel reagents and intermediates for the production thereof, are also described.

摘要翻译： 本发明公开了包含式I化合物和氘代溶剂的组合物。 氘代溶剂在20至25℃的温度下以任何比例与水混溶，并且包含小于5％的残余1H-同位素。 式I化合物的浓度可有利地由1H-QNMR确定。 还描述了制备式I化合物的组合物和盐的方法，以及相关的类似物和新的试剂及其生产中间体。

公开(公告)号：US20160243220A1

公开(公告)日：2016-08-25

申请号：US15024071

申请日：2014-09-24

申请人： THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

发明人： Sathy Balu-Iyer ,  Matthew Pierson Kosloski ,  Krithika Arun Shetty ,  Jennifer Leigh Schneider ,  Anas M. Fathallah

IPC分类号： A61K39/39

CPC分类号： A61K39/39 ,  A61K39/0008 ,  A61K39/001 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/577 ,  C07F9/106

摘要： Provided are method for inducing immune tolerance to antigens including therapeutic antigens. The method comprises administering to an individual OPLS or other lipidic compositions and the antigen, either in a single formulation or as separate formulations where the separate formulations are administered concomitantly or sequentially.

摘要翻译： 提供了诱导对包括治疗性抗原的抗原的免疫耐受性的方法。 该方法包括在单一制剂中或作为分开的制剂施用单独的OPLS或其它脂质组合物和抗原，其中分开的制剂同时或顺序施用。

公开(公告)号：US20140364399A1

公开(公告)日：2014-12-11

申请号：US14362572

申请日：2012-12-06

申请人： OMEGA PROTEIN CORPORATION

发明人： Ernesto Hernandez ,  Marina Rusli ,  Mark Griffin

IPC分类号： C07F9/10 ,  C12P7/64

CPC分类号： C07F9/10 ,  A23D9/013 ,  C07F9/106 ,  C11C3/10 ,  C12P7/6409 ,  C12P7/6481

摘要： The present invention concerns phospholipid compositions having a relatively high concentration of compounds of the following structure (I): wherein at least one of R1 and R2 is palmitoleoyl, myristoleoyl or lauroleoyl and methods for their preparation. The present invention also concerns the use of these phospholipid compositions to treat a variety of disorders by administering the composition to a patient in need thereof.

摘要翻译： 本发明涉及具有相对高浓度以下结构（I）化合物的磷脂组合物：其中R1和R2中的至少一个是棕榈油酰，肉豆蔻酰基或月桂酰基及其制备方法。 本发明还涉及这些磷脂组合物通过将该组合物施用于有需要的患者来治疗多种疾病的用途。

公开(公告)号：US20140275590A1

公开(公告)日：2014-09-18

申请号：US13844379

申请日：2013-03-15

申请人： Cerenis Therapeutics Holding SA

发明人： Daniela Carmen Oniciu ,  Stefan Heckhoff ,  Benoit Oswald ,  Peter Rebmann ,  Andreas Peer ,  Miguel Gonzalez ,  Patrik Sauter

IPC分类号： C07F9/24

CPC分类号： C07F9/65742 ,  C07F9/106

摘要： The present invention includes methods for the synthesis of sphingomyelins and dihydrosphingomyelins. The present invention also includes methods for the synthesis of sphingosines and dihydrosphingosines. The present invention further includes methods for the synthesis of ceramides and dihydroceramides.